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patients’ lives. The objective of this study is to test the psychometric properties of the CIVIQ,
and to validate the use of the questionnaire translated into the Dutch language.
Methods: A standardised questionnaire, including CIVIQ and Short Form (36) Health Survey
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were compared to the SF-36 scores and between different levels of severity of varicose veins.
The CIVIQ’s reliability was assessed using Cronbach’s alpha and testeretest reliability. The
structure was studied using factor analysis. The scores before and after therapy were
compared to assess responsiveness.
Results: There was a response rate of 93.5%. None of 20 items missed <10% of responses, but
three showed ceiling effect. The CIVIQ correlated well with the physical and moderately with
the mental MCS of the SF-36, suggesting a good construct validity of the CIVIQ. The median
CIVIQ scores increased significantly with the severity of varicose veins. The CIVIQ showed an
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CIVIQ in patients with varicose veins. The psychometric properties of the Dutch CIVIQ were
comparable to the original French version.
ª 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Signs of chronic venous insufficiency (CVI) may be found in
about half the adult general population and about a quarter
has lower-extremity varicose veins.1 In addition to cosmetic
impairment, which may lead to psychological discomfort,
common symptoms of CVI and varices are aching, tired
feeling in legs, discomfort, oedema, restless legs and
muscle cramps. The complications of CVI and varicose veins
include eczema, lipodermatosclerosis, ‘atrophy blanche’,
superficial thrombophlebitis and venous ulcers. Not
surprisingly, patients suffering from CVI may have
substantial health-related quality of life (HRQOL) impair-
ment because of the appearance of varicose veins, the
symptoms and complications of CVI.2 Several studies
confirmed that treatment of venous disease improved
HRQOL.3e8 In addition to generic HRQOL instruments, such
as the Short Form (36) Health Survey (SF-36) and EQ-5D,
which have been used in patients with CVI,3e5 disease-
specific instruments provide more specific information
about the impact of CVI and varicose veins on patients’
everyday lives. The two most commonly used disease-
specific HRQOL tools for varicose veins and CVI are the
Aberdeen Varicose Vein Questionnaire (AVVQ)9,10 and the
Chronic Venous Insufficiency Quality of Life Questionnaire
(CIVIQ).2 The focus of the AVVQ is on the presence of
symptoms (i.e., pain and itch) and clinical signs (i.e.,
swelling, discolouration, eczema and ulcer). Only 4 of 13
items address the psychological impact of varicose veins,
especially the functioning domain.11,12 Therefore, the
AVVQ reflects the clinical disease severity and less signifi-
cantly the impact of the disease on a patient’s life. In
contrast to the AVVQ, the CIVIQ has focussed more on the
psychosocial impact of venous disease of the lower limbs
(i.e., its effect on everyday life).2
The CIVIQ was developed by Launois et al. in 1996.2 This
disease-specific questionnaire demonstrated to be valid, to
have an excellent internal consistency, a high reproduc-
ibility and a high responsiveness. It appears to be a valuable
instrument for assessing improvement in patients’ HRQOL
in both clinical practice and trials.13 Although the CIVIQ has
been frequently used and is available in 13 languages, it’s
psychometric properties are not well documented in pop-
ulations other than the original study.6,13e19
The objective of this study is to test several psycho-
metric properties of the CIVIQ in a heterogeneous group of
Dutch patients treated for varicose veins.
Methods
Study population
Between October 2008 and March 2009, all new patients,
who consulted the departments of dermatology andvascular surgery of the Catharina Hospital (Eindhoven, the
Netherlands) for varicose veins, were asked to participate
in this study. At their first visits, patients were asked to
complete the initial standardised questionnaire (defined as
CIVIQ-1). In addition, half of the participants were asked to
complete the HRQOL questionnaire again on the day prior
to their treatment and return them on the treatment day
(i.e., CIVIQ-2). Subsequently, all patients were asked to
complete a third questionnaire at their follow-up visit,
which was at least 4 weeks after treatment (i.e., CIVIQ-3).
Patients’ varicose veins were treated by surgical and non-
surgical methods or a combination (Table 2). The respon-
sible physician was asked to record the ‘C’ of the CEAP
(Clinical, etiologic, anatomic and pathophysiologic) classi-
fication and all performed the treatment for each study
patient.
Questionnaire
Together with a standardised questionnaire, which was
self-administered and included questions about demo-
graphic and disease characteristics, the SF-36 and the CIVIQ
(Appendix I) were included at all visits. The 20 questions of
the CIVIQ (Table 1) result in a global score and four sepa-
rate domain scores: physical (items 5, 6, 7 and 9),
psychological (items 12e20) and social impairment (items
8, 10 and 11) and level of pain (items 1e4). All questions
have a 5-point response category, with higher scores
reflecting more severe impairment. Three separate scores
can be calculated: a score per item (1e5), a score of each
of the four dimensions (0e100) and a global score (value
0e100). Higher scores represent lower HRQOL due to CVI or
varicose veins.2
The translation of the CIVIQ into Dutch was based on
forwardebackward translation as recommended.20 In
brief, three translators, all native speakers in Dutch,
independently translated the questions and the response
options of the English CIVIQ into Dutch. They were
instructed to pay attention to conceptual rather than
literal equivalence, and to choose words and language
constructions that were as simple as possible. The trans-
lators were two employees of a registered translation
office and a dermatologist. The three resulting indepen-
dent forward translations were compared and discussed in
a group meeting of the three translators. Differences were
documented and discussed until consensus was reached
regarding the optimal phrasing of the Dutch CIVIQ. This
common forward translation was then given to two
translators, who were native speakers in English and fluent
in Dutch. They each produced a backward translation that
was both compared with the English CIVIQ for conceptual
equivalence with the original source version. The analysis
was documented and necessary adaptations to the Dutch
Table 1 English version of the CIVIQ.
1. In the past four weeks, if you have felt pain in the ankles or legs, what was the intensity of the pain?
2. During the past four weeks, to what extent did you feel bothered/limited in your work or your other
daily activities because of your leg problem?
3. During the past four weeks, did you sleep bad because of your legs problems, and how often?
During the past four weeks, to what extent dit your leg problems bother/limit you while doing the
movements or activities listed below?
4. standing for a long time
5. climbing stairs
6. crouching, kneeling
7. walking briskly
8. travel by car, bus, plane
9. housework such as working in the kitchen, carrying a child, ironing, cleaning floors or furniture, doing handy work
10. going to discos, weddings, parties, cocktails
11. sporting activities, making physically strenuous efforts
Leg problems can also have an effect on one’s morale. To what extent do the following
sentences correspond to the way you felt during the past four weeks?
12. I feel on edge
13. I become tired quickly
14. I feel I am a burden to people
15. I must always take precautions (such as to stretch my legs, to avoid standing for a long time.)
16. I am embarrassed to show my legs
17. I get irritated easily
18. I feel handicapped
19. I have difficulty getint going in the morning
20. I do not feel like going out
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then administrated to 20 patients with venous disease of
the lower limbs to provide qualitative testing of read-
ability and comprehension. Because this qualitative
testing revealed no problem with the Dutch CIVIQ, it was
subsequently administered in the study population to
collect data for psychometric analysis (Appendix 1).
The SF-36 is a generic HRQOL instrument and has proven
applicability in several areas of disease, including varicose
veins.3e5,7,21e23 The 36 items can be grouped in a mental
and physical component scale (MCS and PCS, respectively).
We included the SF-36 to test construct validity.AnalysisFeasibility
The feasibility of the CIVIQ was evaluated by the overall
response rate. Item difficulty was present, if 10% or more of
the answers of individual items were missing. The score
distribution of all individual items was evaluated by
assessing their floor and ceiling effects (i.e., 70% or more of
the respondents exhibited the worst or best possible score).
If an item loaded <0.40 on the main component of a con-
firmative principal component analysis, it was considered
complex.8
Patients with three or more missing scores were
excluded from the analysis, except from the feasibility
assessment. Missing values were replaced by the median of
the completed items reported by an individual.Structure
Before analysis, a confirmative principal axis factoring
(PAF) followed by promax rotation was performed to test
the structure of the CIVIQ with four dimensions.19 This PAF
analysis reflected 57.18% of the variance of the CIVIQ, but 9
of the 20 items did not load considerably (>0.40) on their
original factor, suggesting that the proposed structure of
four dimensions was suboptimal. Therefore, in this study,
we have focussed on the global score of the CIVIQ and
excluded its four subscales.
Reliability
Cronbach’s alpha (reflecting the internal consistency of an
instrument) was tested using the data from the first pre-
therapy assessment and was considered good, if between
0.7 and 0.9. The degree of testeretest reliability was
estimated by Spearman correlation coefficients (U) of two
assessments in the pre-treatment period about 4 weeks
apart and was considered excellent, if >0.80.
Validity
The construct validity of the CIVIQ (i.e., how it relates to
other HRQOL measures) was tested calculating U between
patients’ CIVIQ scores and the MCS and PCS of the SF-36. To
test the convergent validity of the CIVIQ, we assumed that
patients with higher level of clinical severity (‘C’ from the
CEAP classification; C1 vs. C2 vs C3-6) should have a signif-
icantly higher impact on HRQOL, which was tested using an
analysis of variance (ANOVA).
Table 2 Demographic, disease and therapy characteris-
tics of study population (159 patients).
Characteristics No. of patients (%)
Sex 112 Women (70.4%)
35 Men (22%)
12 unknown
Age, mean (SD, range) 53 years (SD 13.13,
range 17e84 year)
‘C’ of the CEAP classification
C1 14.5%
C2 37.10%
C3 30.20%
C4 11.90%
C5 3.10%
C6 2.50%
unknown 0.60%
Previous therapies for
varicose veins
78 (49.1%)
Sclerocompression therapy 49 (30.8%)
Phlebectomy 8 (5%)
Proximal GSV ligation
(with or without stripping)
31 (19.5%)
Endovenous ablation 3 (1.9%)
Foam sclerotherapy 1 (0.6%)
Unknown 10 (6.3%)
Treated in study period 125
Not treated in study period 34
Treatments during the study
period (n Z )
125
Compression sclerotherapy 43 (27.0%)
Phlebectomy 47 (29.6%)
Proximal GSV ligation
(with or without stripping)
20 (12.6%)
Endovenous ablation 35 (22%)
Foam sclerotherapy 22 (13.8%)
Combination 57 (46.4%)
Phlebectomy and GSV ligation 14
Phlebectomy and EVLA 10
Other 3 (2.4%)
Currently affected leg
Left 38 (23.9%)
Right 33 (20.8%)
Both 78 (49.1%)
Missing 10 (6.3%)
Questionnaire
1. before treatment 159
2. before treatment,
after 4 weeks
73
3. after treatment 115
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Wilcoxon’s signed ranks test was used to compare the CIVIQ
scores prior to and after therapy, to estimate CIVIQ’s
sensitivity to changes brought about by treatment. To
gauge whether the treatment-related difference in CIVIQ
scores was clinically relevant, we used Norman’s rule of
thumb: if the change in score was more than half a standard
deviation (SD) of the distribution of the CIVIQ score prior totherapy, the change was considered clinically meaningful.24
Effect size (d ) was used to measure the strength of the
relationship between two variables in a statistical pop-
ulation. Effect sizes (d ) were interpreted as follows:
dZ 0.2e0.5 is considered a small effect size, dZ 0.5e0.8
is considered a medium effect size and d > 0.8 is a large
effect size.25 Because C1 varicose veins can be considered
a cosmetic condition, Norman’s rule of thumb and d were
calculated for all patients and those with grades of C2 or
more, separately.
The distribution of the global CIVIQ scores was non-
parametric; therefore, it was represented by the median
and its interquartile range (IQR). The other continuous
variables will be presented by a mean and SD. Two sided
p-values of 0.05 or less were considered statistically
significant. All analyses were conducted using SPSS version
15.0. The Medical ethical committee of the Catharina
Hospital (Eindhoven, The Netherlands) granted exempt
status for this observational study. All participants provided
written informed consent.
Results
Study population
Of the eligible 170 patients with varicose veins who were
invited to participate in this study, 159 patients (response
rate 93.5%) completed the initial questionnaire (CIVIQ-1).
After 4 weeks, 80 participants were requested to complete
a second questionnaire before treatment, to assess repro-
ducibility, of whom 73 (response rate 91%) returned the
CIVIQ-2. The CIVIQ-3 (i.e., assessment at least 4 weeks
after therapy) was completed by 93.5% of the 115 treated
patients.
Of the 159 participants, 70.4% were women and the
mean age of the study population was 53 years (SD 13.13,
range 17e84 years; Table 2). Classified according to
C-component of CEAP classification, 14.5% of the partici-
pants were classified in ‘C1’, 37.1% in ‘C2’ and almost half
in ‘C3’ levels or more. About half of the patients were
considered ‘treatment naı¨ve’ patients, those without
previous treatment for varicose veins. The treatment of
varicose veins during the study period was predominantly
EVLA (and some had surgical ligation and stripping) in
combination with phlebectomy and/or sclerotherapy (SCT).
Feasibility
Of the 159 patients who returned the CIVIQ-1, 10 patients
(6.2%) did not respond to three or more items. None of the
individual items were considered suboptimal as missing
responses varied between 0% and 9.4%. However, item 10
(‘going out’) and 11 (‘sports/heavy work’) were missing in
8.8% and 9.4% of the participants, suggesting borderline
feasibility of these items. Interestingly, 11 patients whose
age ranged between 59 and 84 years did not respond to
either of these two items, suggesting they were closely
related.
Of the 20 items, three items demonstrated a substantial
ceiling effect with 70% or more of the respondents indi-
cating the lowest score (item 14 (74.8%); item 18 (79.9%)
05
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Figure 1 Correlation CIVIQ score and C-component of CEAP-
classification. Explanation: To test the convergent validity of
the CIVIQ, we assumed that patients with higher level of clin-
ical severity (‘C’ from the CEAP classification; C1 vs C2 vs C3-6)
should have a significantly higher impact on HRQOL, which was
tested using an ANOVA. The median CIVIQ-1 scores increased
significantly (p < 0.001) with higher ‘C’ levels.
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few patients had the perception to “constitute a burden to
others”, to “feel disabled” or to ”be anxious to meet other
people” because of the complaints of their legs. This
suggests a poor discriminative effect of these three items
for the presence of varicose veins. None of the items
showed floor effects.
Structure
PAF analysis showed that extracted of the first factor
accounted for 43.7% of the variability of the CIVIQ. The
loadings of the 20 CIVIQ items varied between 0.19 and
0.77. Item 16 showed item complexity with a loading of
0.19 on the factor and item 18 was borderline complex with
a loading of 0.39.
Reliability
The item responses of the CIVIQ-1 during the first assess-
ment prior to therapy showed an excellent internal
consistency (Cronbach’s alpha Z 0.94). Among the 73
people who completed the CIVIQ twice prior to therapy
(CIVIQ-1 and -2), the testeretest reliability of the CIVIQ was
also excellent (U Z 0.86). The median global score of the
CIVIQ-1 was 17.50 (IQR 8.13e33.75) and identical to the
median score of CIVIQ-2 (17.50; IQR 7.50e33.75).
Validation
The CIVIQ-1 correlated well with the physical component
scale (PCS) and moderately with the mental component
scale (MCS) of the SF-36 (U Z 0.64 and U Z 0.42,
respectively) suggesting a good construct validity of the
CIVIQ in this population for the physical aspects but less for
the mental aspects of having leg complaints. The median
CIVIQ-1 scores increased significantly with higher ‘C’ levels
(Fig. 1; p < 0.001). After re-grouping the patients, the
median scores increased from 15 (IQR 6.25e26.25) to 23.75
(IQR 13.75e35) to 50 (IQR 24.69e65.94) for C0-1 (n Z 23),
C2-3 (n Z 107) and C4-6 (n Z 28).
Responsiveness
Of the 115 patients who were assessed prior to and at least
4 weeks after therapy (CIVIQ-1 and CIVIQ-3), the CIVIQ
score decreased in 75.65% and increased in 16.52% of
participants. The median CIVIQ score prior to therapy was
18.75 (IQR 11.25e33.75) and significantly decreased to
12.50 (IQR 5.00e22.50) after therapy. The mean global
score decreased from 23.68 (SD 16.04) to 15.66 (SD 13.20).
For all patients, the decrease in the mean CIVIQ score
after therapy was 8.02, which was exactly half the SD of
CIVIQ prior to therapy and is, therefore, in agreement with
Norman’s rule of thumb, clinically significant. In accor-
dance with Norman’s rule of thumb, effect size of the
CIVIQ was 0.50, which is considered a medium effect size,
suggesting that the treatment effect on patients HRQOL
was clinically meaningful. Restricting the analyses to pre-
and post-treatment outcomes in 99 patients, who were
graded C2 or more, showed that both Norman’s rule ofthumb was satisfied (8.42 vs. 7.92) and the effect size
increased to 0.53.
Because the impact of therapy on HRQOL impairment
may differ between subgroup of patients, we investigated
the CIVIQ scores of several subgroups separately. Although
both statistically significant and clinically relevant, the
median CIVIQ score decreased in a more pronounced
manner in the 10 patients who had EVLA plus phlebectomy
(from 20.63 (IQR 8.1e34.06) to 11.25 (IQR 1.25e15.93))
than in the 19 patients who had EVLA only (from 25.00 (IQR
16.25e36.25) to 18.75 (IQR 12.50e28.75)). Other therapies
in combination (e.g., sclerocompression therapy or cross-
ectomy) with EVLA were rare (n < 5).
Patients whose both legs were affected by varicose veins
were treated bilaterally in one session. The significant and
clinically relevant decrement of the median CIVIQ scores of
patients treated bilaterally and those treated unilaterally
was comparable after therapy (from 16.25 (IQR 8.75e36.25)
to 10.00 (IQR 5e22.50) vs. 23.75 (IQR12.50e33.75) to 15.00
(IQR 6.25e28.75)).Discussion
In this study, we have demonstrated that the CIVIQ is
a feasible, valid, reliable and responsive tool in the
assessment of HRQOL in patients with varicose disease.
However, because the CIVIQ’s four dimensional structure
could not be confirmed, we recommend using only the
global score. It appears to be a reliable instrument but the
extremely high internal consistency (>0.90) suggests some
item redundancy, which was also observed in the initial
validation study.18
The change in CIVIQ score after treatment for varicose
veins was statistically significant and clinically meaningful,
especially among patients with clinical relevant disease (C2
or more, according to the CEAP classification). The tests
analysing the responsiveness of the CIVIQ confirm the
importance of the concept of minimal clinical important
1. Als u zich niet gehinderd voelde door of geen
last had van het beschreven symptoom,
ongemak of de gewaarwording.
2, 3, 4 of 5. Als u in meer of mindere mate zich gehinderd
voelt door het beschreven symptoom,
ongemak of de gewaarwording
(5 [ meeste last).
geen pijn lichte pijn matige pijn erge pijn intense pijn
1 2 3 4 5
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to compare the HRQOL scores before and after therapy but
also estimate the size of the effect and whether it is clin-
ically relevant to the patient.7 Categorisation of CIVIQ
scores using anchor-banding techniques would also be very
useful for the interpretation of the scores because it would
allow physicians to categorise patients’ degree of HRQOL
impairment.8 Moreover, the responsiveness findings suggest
that the CIVIQ may not be the most optimal instrument to
assess the impact of varicose veins that are a cosmetic
problem only. In accordance with other studies, the CIVIQ
correlated better with the PCS than with the MCS of the SF-
36, suggesting that the CIVIQ reflects the physical aspects
better than the mental aspect of having varicose veins.3e5
Similar findings have been reported for other varicose
veins-specific HRQOL tools, such as the AVVQ and the
VEINES-QOL.12,26 This is further illustrated by the finding
that the three items exhibiting poor discriminating prop-
erties (ceiling effects) were assessing the psychological
impact of varicose veins, suggesting that this domain may
be less relevant to the majority of patients.
In addition to anatomical success rates, patient-reported
outcomes including some adverse events, such as pain,
HRQOL, treatment satisfaction and preference are increas-
ingly recognised as meaningful outcomes in comparative
clinical trials.3,5,6 It is recommended to use a generic HRQOL
instrument, such as the SF-36, in conjunction with a disease-
specific instrument, such as the CIVIQ or AVVQ, because the
latter two may provide more specific and detailed informa-
tion about the impact of varicose veins and the effect of
treatment.8 Both the CIVIQ and AVVQ have now been vali-
dated in additional patient populations and are able to assess
the impact of varicose veins on patients’ lives. The main
difference between these tools is that the AVVQ includes
multiple items on symptoms, which may affect HRQOL but
may be a different construct than HRQOL, and does not fully
assess the psychosocial impact of varicose veins compared
with the CIVIQ.
In conclusion, this study confirms the feasibility, validity,
reliability and responsiveness of the CIVIQ in a Dutch pop-
ulation of outpatients with varicose veins. The psycho-
metric properties of the Dutch CIVIQ were comparable to
the original French version.2,19geen
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None.Appendix 1. Dutch CIVIQnooit zelden vrij vaak zeer vaak elke nacht
1 2 3 4 5Nederlandstalige CIVIQ
Veel mensen hebben klachten van onaangename gevoelens
in hun benen, al dan niet in samenhang met zichtbare
spataderen aan de benen. Met deze vragenlijst proberen
wij in kaart te brengen hoe vaak deze klachten zich voor-
doen en in welke mate ze invloed hebben op het dagelijkse
leven van betrokkenen.De volgende vragen hebben betrekking op deze onaan-
gename gevoelens. Het is de bedoeling dat U elke vraag
beantwoordt op de volgende wijze:
Geef aan of u datgene wat vermeld is in de vraag hebt
ervaren en, indien dit zo is, in welke mate u hier last van
ondervindt op een schaal van 1 tot en met 5. Omcirkel het
bij u meest passende antwoord bij de desbetreffende
vraag. Het is van groot belang dat alleen waarnemingen van
de afgelopen 4 weken worden vermeld en niet van langer
geleden.
Waardescore:1 Hebt U in de afgelopen 4 weken last gehad van pijn in
de enkels of in de benen en wat was de ernst van deze
pijn
(Omcirkel het meest passende antwoord)2 Voelde u zich in de afgelopen 4 weken gehinderd in Uw
werk of andere activiteiten door Uw beenklachten en in
welke mate?
(Omcirkel het meest passende antwoord)3 Sliep U de afgelopen 4 weken slecht door Uw been-
klachten en hoe vaak?
(Omcirkel het meest passende antwoord)
1 2 3 4 5
Geen last Beetje last Vrij veel last Zeer veel last Gaat gewoon niet
4 Lang staan 1 2 3 4 5
5 Traplopen 1 2 3 4 5
6 Knielen of hurken 1 2 3 4 5
7 Snel wandelen 1 2 3 4 5
8 Reizen met tram/bus/
trein/auto/vliegtuig
1 2 3 4 5
9 Huishoudelijk werk zoals
(koken, voor kind zorgen,
strijken, schoonmaken)
1 2 3 4 5
10 Uitgaan naar discotheek,
feesten, recepties, e.d.
1 2 3 4 5
11 Sport en/of zwaar werk 1 2 3 4 5
252 A.A.M. Biemans et al.4 In welke mate hebben Uw beenklachten U de afgelopen 4 weken gehinderd bij de onderstaande activiteiten?
(Omcirkel achter ieder item het meest passende antwoord)5 Klachten aan de benen kunnen tevens invloed hebben op de gemoedstoestand. In welke mate zijn onderstaande zinnen
op u van toepassing gedurende de afgelopen vier weken?
(Omcirkel steeds het meest bij Uw situatie passende antwoord)Niet Beetje Vrij vaak Heel vaak Altijd
12 Ik voel mij gespannen 1 2 3 4 5
13 Ik ben snel moe 1 2 3 4 5
14 Ik heb het gevoel dat ik anderen tot last ben 1 2 3 4 5
Zie volgende pagina voor de vragen 15 tot en met 20
15 Ik moet steeds voorzorgsmaatregelen nemen,
zoals lang staan vermijden,
benen op tijd strekken, benen hoog leggen,
elastische kousen dragen, enz. om beenklachten te beperken
1 2 3 4 5
16 Ik schaam me om mijn benen te tonen 1 2 3 4 5
17 Ik raak snel geı¨rriteerd 1 2 3 4 5
18 Ik voel mij gehandicapt 1 2 3 4 5
19 Ik heb ’s ochtends moeite om op gang te komen 1 2 3 4 5
20 Ik heb geen zin mij onder de mensen te begeven 1 2 3 4 5References
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